XOMA Royalty (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average – Time to Sell?

by · The Cerbat Gem

XOMA Royalty Corporation (NASDAQ:XOMA – Get Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $30.65 and traded as high as $32.61. XOMA Royalty shares last traded at $32.29, with a volume of 51,704 shares.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Zacks Research cut shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 18th. Wall Street Zen cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of XOMA Royalty in a report on Tuesday. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $69.50.

View Our Latest Stock Report on XOMA

XOMA Royalty Price Performance

The firm has a 50-day moving average of $34.93 and a 200 day moving average of $30.65. The company has a market capitalization of $399.85 million, a PE ratio of -20.83 and a beta of 1.12. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.88 and a quick ratio of 4.88.

XOMA Royalty (NASDAQ:XOMA – Get Free Report) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.33). XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%.The company had revenue of $9.35 million during the quarter, compared to analysts’ expectations of $11.47 million. As a group, research analysts anticipate that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Thomas M. Burns sold 4,330 shares of the stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $35.99, for a total value of $155,836.70. Following the completion of the sale, the chief financial officer directly owned 30,079 shares of the company’s stock, valued at approximately $1,082,543.21. This represents a 12.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On XOMA Royalty

A number of hedge funds have recently modified their holdings of XOMA. CM Management LLC increased its stake in shares of XOMA Royalty by 16.4% in the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock worth $1,276,000 after purchasing an additional 9,000 shares in the last quarter. Deutsche Bank AG increased its stake in XOMA Royalty by 5,087.9% in the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock worth $128,000 after buying an additional 6,309 shares in the last quarter. Nuveen LLC purchased a new stake in XOMA Royalty in the 1st quarter worth $286,000. Stonepine Capital Management LLC raised its holdings in XOMA Royalty by 3.3% during the first quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company’s stock valued at $2,587,000 after acquiring an additional 4,113 shares during the period. Finally, Woodline Partners LP lifted its position in shares of XOMA Royalty by 7.9% in the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after acquiring an additional 12,284 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors.

About XOMA Royalty

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

Featured Stories